about
Antagonist properties of Conus parius peptides on N-methyl-D-aspartate receptors and their effects on CREB signalingFailures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insultsProteolytic fragments of laminin promote excitotoxic neurodegeneration by up-regulation of the KA1 subunit of the kainate receptorThe role of neuronal complexes in human X-linked brain diseasesN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseIon channels as drug targets in central nervous system disordersMechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding coreSeparation of Domain Contacts Is Required for Heterotetrameric Assembly of Functional NMDA ReceptorsPerspective of synaptic protection after post-infarction treatment with statinsThe chemical biology of clinically tolerated NMDA receptor antagonistsThe serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's diseaseTherapeutic use of PDZ protein-protein interaction antagonismTFP5 peptide, derived from CDK5-activating cofactor p35, provides neuroprotection in early-stage of adult ischemic strokeSynergy of Omeprazole and Praziquantel In Vitro Treatment against Schistosoma mansoni Adult WormsThe serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptorsDementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South AmericaPharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular diseaseStructural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies.Advances in the treatment of anxiety: targeting glutamate.Efficacy of 3,5-dibromo-L-phenylalanine in rat models of stroke, seizures and sensorimotor gating deficit.Increased NRG1-ErbB4 signaling in human symptomatic epilepsy.Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice.Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease.The role of canonical transient receptor potential channels in seizure and excitotoxicityInverse relationship between seizure expression and extrasynaptic NMDAR function following chronic NMDAR inhibition.Protection after stroke: cellular effectors of neurovascular unit integrity.Therapeutic use of creatine in brain or heart ischemia: available data and future perspectives.NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growthA steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivityMitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases.Pregnenolone sulfate and its enantiomer: differential modulation of memory in a spatial discrimination task using forebrain NMDA receptor deficient miceUpregulation of protein phosphatase 2A and NR3A-pleiotropic effect of simvastatin on ischemic stroke rats.Intravenous administration of achyranthes bidentata polypeptides supports recovery from experimental ischemic stroke in vivo.Myelin-associated glycoprotein protects neurons from excitotoxicity.Intracisternal administration of NR2 subunit antagonists attenuates the nociceptive behavior and p-p38 MAPK expression produced by compression of the trigeminal nerve root.Mind bomb-2 is an E3 ligase that ubiquitinates the N-methyl-D-aspartate receptor NR2B subunit in a phosphorylation-dependent manner.Down-regulation of the RNA editing enzyme ADAR2 contributes to RGC death in a mouse model of glaucoma.Presenilin1/gamma-secretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding proteinMotor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease
P2860
Q21132410-3D768ED6-83CD-4C20-96C8-329ED13506CEQ24558984-3C25EF90-F251-4D77-9502-E07A43802231Q24642234-FC2B466D-DF44-4BC8-BE23-6C2066B5A0D4Q24680472-8A67C7C9-A6B8-4A94-B4DF-55411B0EEC8BQ26825619-140D812B-871F-4DAD-996A-495B442C7BE8Q27004533-5394A77B-9842-4A95-B61A-9A69ED25E66DQ27641433-2E7F1EC2-9607-47B8-B48E-4B5E394FC18FQ27667242-F83C053E-EB45-4BB5-B39A-7EDC77959F34Q28080692-85FD7CCB-2942-4159-A47B-6ED678C5F500Q28248958-2F970E6F-8FF7-4ED3-8646-C1C768DD7D92Q28251394-307B2724-FC44-4693-B9C8-A68FEE6E517FQ28284263-310FB857-F0F6-4A4D-ADCD-A6661EB84866Q28397588-F1BD967C-80E2-41ED-84E7-A21DD2D1A3D3Q28548401-A3BF2C51-A98D-4770-8017-672FB4812FBBQ28771352-897FE23A-8265-4D74-9D02-C99395444DF4Q28817091-014FB839-E0DA-4B11-A879-7762BC89DBDAQ29243373-07507570-A98C-4D0E-8E38-5D3550EFBB9BQ30373373-5DAD7431-3F9A-41EA-8450-B3BA2FA84D9BQ30457479-1F83816E-8DBC-4CF8-BABA-068075E7B4CEQ30478344-B0D89A43-58F1-44D8-8B49-39E9FFC22ABEQ33669944-378691C2-09FF-4300-95A3-F89931FBCCBAQ33719741-34E766D8-D532-46D0-B7A7-41147E70E624Q33788860-B17F3C52-51DD-4A6F-8376-A98B518AA3DFQ33798453-B656E7BA-0E55-444E-A644-8E64A17FA3AEQ33883856-B6AD766B-F6EB-4422-A192-8C1A83789B49Q34015816-4363E92E-B371-4B0E-8F6D-3DF902A8D403Q34043168-7C5DC260-FD62-48D5-BD79-9EBF724C86ABQ34089086-C69E1E2B-4919-4B42-8F5B-81CAF403AB20Q34098628-BFE8E2E0-A922-48F8-91AE-8F6D8F2C783CQ34332564-30033381-0351-4125-8AF7-7A5A90AC6F58Q34502221-245DAFF1-09AF-4642-941F-4611C17DA9C9Q34516771-924A0E27-C9C5-46A6-B46A-D8B96984A490Q34516850-731451D1-199F-4280-8676-98D1B0F5D3BBQ34611715-A3E03122-AA83-448A-9D47-9455A5F9396BQ34686899-F6A988CE-DB70-4242-BA9B-D4D856D9D737Q35069330-8CCD456A-7339-4453-A235-84C8E7C4B15BQ35071725-62F7EAA2-5B67-47FB-94A4-8350C86708EFQ35114509-EBD6E721-0FA4-49F5-B1FC-E32DF5B815B7Q35225098-C655F504-E5DE-4604-80F6-7464E0550EE2Q35480296-2D853498-869A-41E2-9217-1F0F4AEFC1AF
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
NMDA receptor pathways as drug targets.
@ast
NMDA receptor pathways as drug targets.
@en
NMDA receptor pathways as drug targets.
@nl
type
label
NMDA receptor pathways as drug targets.
@ast
NMDA receptor pathways as drug targets.
@en
NMDA receptor pathways as drug targets.
@nl
prefLabel
NMDA receptor pathways as drug targets.
@ast
NMDA receptor pathways as drug targets.
@en
NMDA receptor pathways as drug targets.
@nl
P356
P1433
P1476
NMDA receptor pathways as drug targets.
@en
P2093
John A Kemp
Ruth M McKernan
P2888
P304
P356
10.1038/NN936
P407
P478
P577
2002-11-01T00:00:00Z
P5875
P6179
1016862545